Diagnostic indicators and lifestyle interventions of metabolic-associated fatty liver disease

Frontiers in Nutrition, Journal Year: 2024, Volume and Issue: 11

Published: June 14, 2024

MAFLD has become a major global health problem and is the leading cause of liver disease worldwide. The progresses from simple fatty to gradual fibrosis, which cirrhosis even hepatocellular cancer. However, methods currently used for diagnosis are invasive do not facilitate clinical assessment condition. As result, research on markers increasing. In addition, there no medications treatment MAFLD, lifestyle interventions remain effective in prevention MAFLD. this review, we attempt make summary emerging diagnostic indicators provide new insights into

Language: Английский

Predictors of Hepatic Fibrosis in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease

Biomedicines, Journal Year: 2024, Volume and Issue: 12(11), P. 2542 - 2542

Published: Nov. 7, 2024

Approximately 25% of the world's population and more than 60% patients with type 2 diabetes (T2D) have metabolic-dysfunction-associated steatotic liver disease (MASLD). The association between these pathologies is an important cause morbidity mortality in Brazil worldwide due to high frequency advanced fibrosis cirrhosis. objective this study was determine epidemiologic clinical-laboratory profile T2D MASLD treated at endocrinology reference service a state northeastern Brazil, investigate anthropometric laboratory measurements.

Language: Английский